The objective is to describe the outcomes of patients with human immunodeficiency virus (HIV) infection who received extracorporeal membrane oxygenation (ECMO) for severe respiratory failure (SRF). The design and setting was a single centre retrospective observational case series, from January 2012 to June 2017, at a tertiary university hospital and regional referral centre for ECMO in the United Kingdom. The participants were all patients referred with SRF and HIV infection. The main outcome measure was patient 90-day survival. Twenty-four patients were referred, of whom nine received ECMO. Six out of nine (67%) of patients were alive at 90 days. Median duration of ECMO was 18 days. There were no identified differences between survivors and non-survivors. ECMO can be used successfully in selected patients with HIV and SRF, including those with poor HIV control and high illness severity. HIV status alone should not exclude patients from treatment with extracorporeal therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0956462418805606 | DOI Listing |
ASAIO J
January 2025
From the Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
Right ventricular injury (RVI) in respiratory failure receiving veno-venous extracorporeal membrane oxygenation (VV ECMO) is associated with significant mortality. A scoping review is necessary to map the current literature and guide future research regarding the definition and management of RVI in patients receiving VV ECMO. We searched for relevant publications on RVI in patients receiving VV ECMO in Medline, EMBASE, and Web of Science.
View Article and Find Full Text PDFASAIO J
January 2025
Division of Pediatric Cardiology, Department of Pediatrics, Heart Institute, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado.
Venoarterial extracorporeal membrane oxygenation (VA ECMO) may provide temporary hemodynamic support for patients with severe vasodilatory shock due to toxicologic ingestion. In a series of 10 cases of children less than 18 years of age who received VA ECMO support for toxicologic-induced vasodilatory shock, there were eight survivors and two nonsurvivors who died of significant neurologic injury. Upon initiation of ECMO support, survivors had decline in Vasoactive-Inotrope Scores (VIS).
View Article and Find Full Text PDFEur J Cardiothorac Surg
December 2024
University Clinic for Cardiac Surgery, Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Objectives: The study aim was to investigate the outcomes and risk factors for mortality in patients undergoing surgery for acute type A aortic dissection (ATAAD) receiving concomitant veno-arterial extracorporeal membrane oxygenation (ECMO) support.
Methods: Patients from five European centers who underwent surgery for ATAAD and received perioperative veno-arterial ECMO support were included. A multivariable binary logistic regression analysis was performed to identify risk factors for thirty-day mortality.
Pediatr Crit Care Med
January 2025
Division of Pediatric Nephrology, Pediatric Acute Kidney Care Program, Medical University of South Carolina, Charleston, SC.
Crit Care Resusc
December 2024
Department of Intensive Care, Alfred Health, 55 Commercial Road, Melbourne, 3181, VIC, Australia.
Objective: To describe the epidemiology and clinical features of pressure injury (PI) development in adult patients supported with extracorporeal membrane oxygenation (ECMO).
Design: Retrospective, observational, cohort study from January 2018 to May 2023.
Setting: A single-centre high-volume ECMO specialist intensive care unit (ICU).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!